Free Trial

Innoviva (INVA) Competitors

Innoviva logo
$18.92 +0.10 (+0.53%)
As of 10:17 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

INVA vs. BCRX, LGND, FOLD, MNKD, CLDX, DVAX, NVAX, OPK, GERN, and RGLS

Should you be buying Innoviva stock or one of its competitors? The main competitors of Innoviva include BioCryst Pharmaceuticals (BCRX), Ligand Pharmaceuticals (LGND), Amicus Therapeutics (FOLD), MannKind (MNKD), Celldex Therapeutics (CLDX), Dynavax Technologies (DVAX), Novavax (NVAX), OPKO Health (OPK), Geron (GERN), and Regulus Therapeutics (RGLS). These companies are all part of the "biotechnology" industry.

Innoviva vs.

Innoviva (NASDAQ:INVA) and BioCryst Pharmaceuticals (NASDAQ:BCRX) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, earnings, media sentiment, institutional ownership, community ranking, risk and dividends.

99.1% of Innoviva shares are held by institutional investors. Comparatively, 85.9% of BioCryst Pharmaceuticals shares are held by institutional investors. 2.3% of Innoviva shares are held by company insiders. Comparatively, 4.8% of BioCryst Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

BioCryst Pharmaceuticals received 193 more outperform votes than Innoviva when rated by MarketBeat users. Likewise, 67.16% of users gave BioCryst Pharmaceuticals an outperform vote while only 57.52% of users gave Innoviva an outperform vote.

CompanyUnderperformOutperform
InnovivaOutperform Votes
306
57.52%
Underperform Votes
226
42.48%
BioCryst PharmaceuticalsOutperform Votes
499
67.16%
Underperform Votes
244
32.84%

In the previous week, BioCryst Pharmaceuticals had 1 more articles in the media than Innoviva. MarketBeat recorded 11 mentions for BioCryst Pharmaceuticals and 10 mentions for Innoviva. Innoviva's average media sentiment score of 1.42 beat BioCryst Pharmaceuticals' score of 1.10 indicating that Innoviva is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Innoviva
8 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
BioCryst Pharmaceuticals
10 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Innoviva currently has a consensus target price of $55.00, suggesting a potential upside of 190.70%. BioCryst Pharmaceuticals has a consensus target price of $16.56, suggesting a potential upside of 59.28%. Given Innoviva's stronger consensus rating and higher possible upside, equities analysts plainly believe Innoviva is more favorable than BioCryst Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Innoviva
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
BioCryst Pharmaceuticals
0 Sell rating(s)
1 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.89

Innoviva has a beta of 0.35, meaning that its share price is 65% less volatile than the S&P 500. Comparatively, BioCryst Pharmaceuticals has a beta of 1.08, meaning that its share price is 8% more volatile than the S&P 500.

Innoviva has a net margin of 18.31% compared to BioCryst Pharmaceuticals' net margin of -30.01%. Innoviva's return on equity of 20.84% beat BioCryst Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Innoviva18.31% 20.84% 11.38%
BioCryst Pharmaceuticals -30.01%N/A -24.06%

Innoviva has higher earnings, but lower revenue than BioCryst Pharmaceuticals. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Innoviva$369.84M3.21$179.72M-$1.01-18.73
BioCryst Pharmaceuticals$503.49M4.32-$226.54M-$0.26-39.98

Summary

Innoviva and BioCryst Pharmaceuticals tied by winning 9 of the 18 factors compared between the two stocks.

Get Innoviva News Delivered to You Automatically

Sign up to receive the latest news and ratings for INVA and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

INVA vs. The Competition

MetricInnovivaPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$1.18B$6.47B$5.31B$8.28B
Dividend YieldN/A2.64%5.20%4.10%
P/E Ratio27.358.9026.7319.58
Price / Sales3.21257.08387.44119.65
Price / Cash5.1765.8538.2534.62
Price / Book1.776.406.744.47
Net Income$179.72M$143.98M$3.23B$248.22M
7 Day Performance1.83%-0.09%-0.05%-1.32%
1 Month Performance2.99%1.55%8.51%10.73%
1 Year Performance19.82%-0.62%18.25%8.40%

Innoviva Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
INVA
Innoviva
4.3358 of 5 stars
$18.92
+0.5%
$55.00
+190.7%
+17.0%$1.18B$369.84M27.35100Positive News
BCRX
BioCryst Pharmaceuticals
4.6177 of 5 stars
$10.34
+3.7%
$16.56
+60.1%
+56.0%$2.16B$503.49M-16.95530Positive News
Analyst Upgrade
LGND
Ligand Pharmaceuticals
4.3412 of 5 stars
$106.38
+1.8%
$146.14
+37.4%
+16.1%$2.05B$181.49M42.3880Positive News
FOLD
Amicus Therapeutics
3.9848 of 5 stars
$6.21
+3.8%
$16.22
+161.2%
-35.6%$1.91B$543.14M-34.50480Positive News
High Trading Volume
MNKD
MannKind
2.9214 of 5 stars
$4.81
+5.5%
$10.00
+107.9%
-12.4%$1.46B$297.60M68.71400
CLDX
Celldex Therapeutics
1.9657 of 5 stars
$20.18
+10.1%
$53.90
+167.1%
-46.5%$1.34B$7.02M-7.85150Positive News
DVAX
Dynavax Technologies
4.1554 of 5 stars
$9.85
+4.7%
$24.00
+143.7%
-17.3%$1.18B$294.62M54.72350High Trading Volume
NVAX
Novavax
3.7195 of 5 stars
$6.34
+6.2%
$17.71
+179.4%
-53.6%$1.02B$682.16M-2.811,990
OPK
OPKO Health
4.3183 of 5 stars
$1.26
+1.6%
$2.75
+118.3%
-3.8%$999.25M$689.41M-6.634,200
GERN
Geron
4.1295 of 5 stars
$1.28
+8.5%
$5.06
+295.5%
-59.6%$815.26M$116.29M-4.0070Positive News
Gap Down
RGLS
Regulus Therapeutics
1.2871 of 5 stars
$7.87
flat
$8.50
+8.0%
+312.0%$521.33MN/A-7.3630

Related Companies and Tools


This page (NASDAQ:INVA) was last updated on 5/23/2025 by MarketBeat.com Staff
From Our Partners